HMGA1b

HMGA1b is a protein encoded by the HMGA1b gene in humans, a member of the high‑mobility group (HMG) family of architectural transcription factors. The protein belongs to the HMGA subfamily, which includes HMGA1a, HMGA1b, and HMGA2. Like its close relative HMGA1a, HMGA1b contains three AT‑hook motifs that enable binding to the minor groove of AT‑rich sequences in DNA. This binding induces chromatin remodeling and facilitates the assembly of transcriptional complexes on target gene promoters. The association of HMGA1b with DNA does not require the presence of other cofactors, and the protein can act as an architectural cue to change DNA topology, thereby influencing gene expression.

The two main isoforms of HMGA1, HMGA1a and HMGA1b, arise through alternative splicing of the same gene; both isoforms are expressed in a variety of tissues, but their expression levels vary during differentiation and development. In embryonic stem cells, HMGA1b is highly expressed, suggesting a role in maintaining pluripotency and regulating early lineage decisions. During differentiation to specialized cell types, HMGA1b levels generally decline, while HMGA1a becomes predominant. This dynamic expression pattern indicates that HMGA1b may have distinct functional roles from HMGA1a, potentially related to distinct sets of target genes or developmental cues.

HMGA1b has been investigated in the context of cancer biology. Overexpression of HMGA1b has been reported in several tumor types, including hepatocellular carcinoma, colorectal carcinoma, and breast cancer. In these settings, increased HMGA1b correlates with enhanced cell proliferation, invasiveness, and poor clinical outcomes. Functional studies suggest that HMGA1b can activate oncogenic signaling pathways, such as the PI3K/Akt pathway, by upregulating the transcription of genes involved in cell cycle progression and survival. Additionally, HMGA1b has been implicated in the epithelial‑to‑mesenchymal transition (EMT) process, a key step in metastasis.

Research into HMGA1b also highlights its potential as a therapeutic target. Small molecules that disrupt AT‑hook DNA interactions or antisense oligonucleotides that downregulate HMGA1b expression are being explored in pre‑clinical models. However, because HMGA1b also plays roles in normal development and gene regulation, therapeutic approaches must consider potential off‑target effects. Continued studies are therefore needed to elucidate the precise mechanisms of HMGA1b action and to assess its viability as a selective drug target.